Clinical trials: Alcohol Disorders
Acute on Chronic Liver Failure, Alcoholic Hepatitis
CytoSorb® in Patients With Acute on Chronic Liver Failure
The objective of this study is to assess the safety and performance of the CytoSorb® therapy in patients with Acute on Chronic Liver Failure (ACLF) grade ≥ 2 due to a severe alcohol induced hepatitis (Maddrey DF > 32) and a…
- Trial name
- HepOnFire (NCT05131230)
- Testing
- CytoSorb® treatment
- Where
- 2 sites in Germany
- Sponsor
- CytoSorbents Europe GmbH
Alcohol Addiction
Soberlink - MAP Outcomes Study Protocol
The purpose of this study is to show the effectiveness of Soberlink's remote alcohol monitoring system integrated with MAP's patient engagement platform (EHR) to monitor a sample size of at-risk alcohol use disorder (AUD)…
- Trial name
- NCT03190356
- Testing
- Soberlink Cellular Device
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Soberlink Healthcare LLC
Alcohol Use Disorder
A Study of New Treatment for Excessive Alcohol Users by Electric Stimulation of Nerves Around Ear
Alcohol Use Disorders (AUD's) are a major health and social problem. Relapse is a rule rather than an exception in alcohol dependence, leading to poor outcomes. Craving are frequently associated with relapse.
- Trial name
- NCT04106739
- Testing
- Drug Relief V(version) 2.0 Auricular Percutaneous Electrical Neural Field Stimulation (PENFS)
- Where
- India
- Volunteers
- 44 people
- Sponsor
- DyAnsys, Inc.
Alcohol Dependence
A Single-center, Open-label, Single-dose Study Investigating the Safety, Tolerability, and Pharmacokinetic Properties of Nalmefene 10 mg Tablets in Healthy Japanese Male Subjects
The safety, tolerability, and pharmacokinetics of nalmefene at a single oral dose of 10 mg in healthy Japanese male subjects will be evaluated.
- Trial name
- NCT02679469
- Testing
- nalmefene hydrochloride 10 mg
- Where
- Japan
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Substance Use Disorder, Drug Dependence,
Impact of Prevention Awareness Group (PAG) on Treatment Attendance and Drug Abstinence Among Substance User
Substance Use Disorder has been showing a rising trend all over the world including India. The project tested whether a Integrated community wide effort of Prevention and Awareness Groups (PAG) to manage substance use would have…
- Conditions
- Substance Use Disorder, Drug Dependence,, Alcohol Dependence
- Trial name
- NCT02173041
- Testing
- Prevention Awareness Groups (PAG), Standard Care
- Where
- India
- Volunteers
- 152 people
- Sponsor
- Macmillan Research Group UK
Prostate Disease, BPH
Safety/Tolerability Study of Alcohol Injection for Treatment of BPH (Enlarged Prostate)
Multi-center, prospective randomized dosing and safety research study. A maximum of 150 men will be enrolled in the study. Qualifying patients will receive one of three possible doses of the study drug.
- Conditions
- Prostate Disease, BPH, Benign Prostatic Hyperplasia, Benign Prostatic Hypertrophy
- Trial name
- NCT00037141
- Testing
- dehydrated alcohol
- Volunteers
- 150 people
- Sponsor
- American Medical Systems
Substance Abuse
Substance Treatment and HIV Testing and Referral System
The lack of substance screening and referral in healthcare settings is a significant problem with far-reaching consequences, including excess morbidity, premature mortality, and inflated healthcare costs.
- Trial name
- STaRS (NCT01488630)
- Testing
- STaRS
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Polaris Health Directions
Alcohol Dependence
ALK33-005: A Study of ALKS33 (RDC-0313) in Adults With Alcohol Dependence
This study will evaluate the safety and efficacy of ALKS33 (RDC-0313) compared with placebo in adults with alcohol dependence. There will be 11 study visits conducted over a period of about 4 months.
- Trial name
- NCT00981617
- Testing
- ALKS33 (RDC-0313) (1 mg), ALKS33 (RDC-0313) (2.5 mg), ALKS33 (RDC-0313) (10 mg)
- Where
- 27 sites in United States
- Volunteers
- 406 people
- Sponsor
- Alkermes, Inc.
Alcohol Abuse
Adaptive Goal-Directed Adherence Tracking and Enhancement
Talaria, Inc., has designed an adherence tracking and enhancement system, called AGATE, which uses the text messaging and internet capabilities of modern cellular phones to address the problem of medication adherence in clinical…
- Trial name
- AGATE (NCT01349985)
- Testing
- AGATE, SASED
- Where
- United States
- Volunteers
- 136 people
- Sponsor
- Talaria, Inc
Headache, Nausea
Evaluation of a Fixed Combination of Herbal Extracts to Prevent Symptoms Alcohol-induced Hangovers
The primary objective of the study is to test whether the tested Product LACIME Anti-hangover is effective in preventing the signs and symptoms of alcohol-induced hangover (such as headache, impaired memory, depression, anxiety…
- Conditions
- Headache, Nausea, Dizziness, Sleepiness
- Trial name
- LACIME (NCT04183842)
- Testing
- LACIME Anti-hangover
- Where
- Armenia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Incara Lab
Alcohol Use Disorder
A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder
The purpose of this study is to see if brenipatide when compared to a placebo works and is safe for participants with moderate-to-severe Alcohol Use Disorder (AUD). Participation in this study will last approximately 56 weeks.
- Trial name
- RENEW-ALC-1 (NCT07219966)
- Testing
- LY3537031
- Where
- 117 sites in United States, Belgium and 6 more
- Volunteers
- 1,100 people
- Sponsor
- Eli Lilly and Company
Alcohol Use Disorder (AUD)
A Study to Investigate the Safety and Efficacy of TMP-301 Compared to Placebo in Adult Patients With Alcohol Use Disorder
TMP-301 has been shown in preclinical models to reduce consumption of alcohol and other addictive substances. It has been tested in healthy subjects and has been found to be safe and tolerated at doses predicted to be efficacious…
- Trial name
- LIBERATE-A (NCT06648655)
- Testing
- TMP-301
- Where
- 14 sites in United States
- Volunteers
- 110 people
- Sponsor
- Tempero Bio, Inc.
Hypertension
TARGET BP I Clinical Trial
The TARGET BP I Trial is a randomized, blinded, multi-center, international, sham-procedure controlled trial, comparing renal denervation performed with the Peregrine System Kit in the treatment group to the sham control group…
- Trial name
- TARGET BP I (NCT02910414)
- Testing
- Dehydrated alcohol
- Where
- 5 sites in United States
- Volunteers
- 300 people
- Sponsor
- Ablative Solutions, Inc.
Alcohol Use Disorder (AUD)
Study of DCR-AUD in Healthy Volunteers
DCR-AUD will be evaluated for safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy volunteers.
- Trial name
- NCT05021640
- Testing
- DCR-AUD
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Erectile Dysfunction
A Phase I Crossover Study of the Hemodynamic Interactions of Avanafil & Alcohol in Healthy Male Subjects.
The purpose of this study is primarily to evaluate whether taking avanafil with alcohol causes the blood pressure to fall.
- Trial name
- NCT01054859
- Testing
- avanafil, alcohol
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- VIVUS LLC
Hepatorenal Syndrome
A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin
This study is designed to evaluate the efficacy and safety of intravenous terlipressin versus placebo for the treatment of type 1 hepatorenal syndrome (HRS) in participants receiving standard of care albumin therapy.
- Trial name
- NCT01143246
- Testing
- Terlipressin
- Where
- 73 sites in United States, Canada
- Volunteers
- 196 people
- Sponsor
- Mallinckrodt
Intrahepatic Cholestasis Associated With Alcoholic Liver Disease
Study With Heptral in Subjects With Liver Disease Due to Alcohol Consumption
A research study of an approved drug called Heptral®, ademetionine, to treat adults with intrahepatic cholestasis (a condition where bile cannot flow from the liver to the duodenum) in pre-cirrhotic and cirrhotic states.
- Trial name
- NCT02200029
- Testing
- Ademetionine IV+tablet, Ademetionine tablet
- Where
- 12 sites in Russia
- Volunteers
- 75 people
- Sponsor
- Abbott
Alcohol Use Disorder
Contingency Management for Alcohol Use Disorder
Randomized pilot study of a device (smartphone app) that poses non-significant risk to participants and is exempt from Investigational Device Exemption regulations [21 Code of Federal Regulations 812.2(c)
- Trial name
- NCT03701204
- Testing
- DynamiCare Rewards
- Where
- 2 sites in United States
- Volunteers
- 61 people
- Sponsor
- DynamiCare Health
Insomnia
Safety, Tolerability and Efficacy Study of V117957 in Subjects With Insomnia Associated With Alcohol Cessation
The purpose of this study is to evaluate the safety, tolerability and efficacy of V117957 in subjects with alcohol use disorder (AUD) who experience insomnia associated with alcohol cessation, compared to placebo.
- Trial name
- NCT04035200
- Testing
- V117957 tablets
- Where
- 17 sites in United States
- Volunteers
- 114 people
- Sponsor
- Imbrium Therapeutics
Non-Alcoholic Fatty Liver Disease, Liver Disease; Alcohol-Related
FibroScan-Reproducibility and Repeatability Study
Chronic liver disease (CLD) is a serious health issue worldwide, often progressing without symptoms until advanced stages with risks of complications like liver cancer and cirrhosis.
- Trial name
- FibroScan-RR (NCT06877026)
- Testing
- FibroScan, Liver Enzymes
- Where
- United Kingdom
- Volunteers
- 108 people
- Sponsor
- Echosens